BeOne Medicines Ltd.
ONC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ONC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ONC
BeOne Medicines Ltd. is a global biotech company focused on developing and commercializing innovative oncology medicines, with a strong commercial portfolio led by BRUKINSA and a deep pipeline of early- and late-stage candidates.
Key risk: High debt level
BioSniper Score
Based on 6 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 78 clinical trials · 20 catalysts · 2 FDA decisions for BeOne Medicines Ltd..
BeOne Medicines Ltd. is a global biotech company focused on developing and commercializing innovative oncology medicines, with a strong commercial portfolio led by BRUKINSA and a deep pipeline of early- and late-stage candidates.
- Revenue of $1,705.1M and net income of $237.0M for the six months ended June 30, 2026 [sec].
- Cash and equivalents of $5,280.7M as of June 30, 2026, with shareholders' equity of $3,770.5M and total debt of $979.6M [sec].
- BRUKINSA has emerged as the global revenue leader in the BTKi class, maintaining U.S. new patient share lead across BTKi [sec · filed 2026-04-28].
- Net income turned around to approximately $287M for FY2025 from a net loss of approximately $645M for FY2024 [sec · filed 2026-04-28].
- Employee workforce increased by approximately 14.5% to about 11,988 as of March 31, 2026 [sec · filed 2026-04-28].
What works
- BRUKINSA is the global revenue leader in the BTKi class and maintains U.S. new patient share lead across BTKi, indicating strong commercial traction [sec · filed 2026-04-28].
- The company achieved a turnaround to net income of ~$287M in FY2025 from a net loss of ~$645M in FY2024, demonstrating improving profitability [sec · filed 2026-04-28].
- A strong balance sheet with $5,280.7M in cash and equivalents as of June 30, 2026 provides substantial resources for R&D and operations [sec].
- The company has a large internal clinical development team of nearly 3,700 and has enrolled more than 24,000 patients in over 150 trials, supporting efficient drug development [sec · filed 2025-04-07].
What to weigh
- Total debt of $979.6M as of June 30, 2026 represents a significant financial obligation [sec].
- R&D expenses continue to increase, with internal R&D expense rising by 15.6% to $364.7M in Q2 2026, driven by pipeline investments [sec_mda · as of 2026-08-05].
- The company faces risks from macroeconomic conditions, competition, and reliance on third parties for manufacturing and other services [sec_mda · as of 2026-08-05].
- The expanding employee workforce (up 14.5%) places increasing demand on equity incentive plans, potentially diluting existing shareholders [sec · filed 2026-04-28].
From the filings
Quoted directly from source documents.
BRUKINSA is the global revenue leader in the BTKi class.
“BRUKINSA:Emerged as the global revenue leader in the BTKi class, maintaining U.S. new patient share lead across BTKi”
SEC filings · April 28, 2026
Net income turned around to positive in FY2025.
“Net income of the Group turned around to approximately US$287 million for FY2025, from a net loss of approximately US$645 million for FY2024.”
SEC filings · April 28, 2026
The company has a large clinical development team and extensive trial experience.
“Our nearly 3,700-strong internal clinical development team has pioneered a "Fast to Proof-of-Concept" approach, delivering speed and cost-advantages in early-stage development. Operating across 45 countries and regions, our team has enrolled more than 24,000 patients in more than 150 trials to date”
SEC filings · April 7, 2025
Employee workforce increased by 14.5%.
“the employee workforce of the Group has increased by approximately 14.5% from approximately 10,473 employees as at January 1, 2024 to approximately 11,988 employees as at March 31, 2026.”
SEC filings · April 28, 2026
Catalyst timeline
- 2026-08-31 · Phase2_Start · tislelizumab — Phase 2 Start — Initiation of a Phase 2 study of tislelizumab with alternative dosing schedules plus chemotherapy.
- 2026-09-04 · Phase1_Start — Phase 1 Start — Initiation of a Phase 1a/1b study investigating safety, tolerability, PK, PD, and other endpoints.
- 2026-10-01 · Phase2_Start — Phase 2 Start — Initiation of a Phase 1/2a open-label, dose-finding and expansion study.
- 2026-12-31 · Phase3_Topline · zanubrutinib — Phase 3 Topline — Topline data readout from a long-term extension study of zanubrutinib regimens.
- 2027-01-30 · Phase3_Topline — Phase 3 Topline — Topline data from a Phase 3 randomized, double-blind, placebo-controlled maintenance trial.
- 2027-03-31 · Phase3_Topline · tislelizumab — Phase 3 Topline — Topline data from a Phase 3 randomized, double-blind, placebo-controlled study of tislelizumab.
- 2027-10-01 · Phase3_Topline — Phase 3 Topline — Topline data from a Phase 2/3 multicenter, randomized, active-controlled, open-label study.
- 2027-10-31 · Phase3_Topline · bgb-3111 — Phase 3 Topline — Topline data from an international Phase 3 open-label, randomized study of BGB-3111 compared with bendamustine plus rituximab.
Risks & what to watch (4)›
Key risks
- High debt level — Total debt of $979.6M as of June 30, 2026, representing a significant financial obligation [sec].
- Rising R&D expenses — Internal R&D expense increased 15.6% to $364.7M in Q2 2026, driven by pipeline investments [sec_mda · as of 2026-08-05].
- Dependence on third parties — Reliance on third parties for manufacturing, supply, and other services poses operational risks [sec_mda · as of 2026-08-05].
- Macroeconomic and competitive pressures — Macroeconomic conditions and competition from other therapies could impact market access and sales [sec_mda · as of 2026-08-05].
What to watch
- Upcoming Phase 3 topline data for zanubrutinib (BGB-3111) expected by December 31, 2026 [catalyst_timeline].
- Phase 3 topline data for tislelizumab expected by March 31, 2027 [catalyst_timeline].
- Initiation of multiple Phase 1 and Phase 2 trials in late 2026, including tislelizumab alternative dosing and a Phase 1a/1b study [catalyst_timeline].
- Continued commercial performance of BRUKINSA and TEVIMBRA, which drove revenue growth in FY2025 [sec · filed 2026-04-28].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run BeOne Medicines Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BeOne Medicines Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.77 · 4% dilution
Lead: Approved
2 candidates
20 upcoming, next in ~1d
0 buys · 132 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
277
Total value held
$8.26B
| Holder | Shares | Value |
|---|---|---|
| baker bros. advisors lp | 8,799,053 | $2.61B |
| primecap management co/ca/ | 4,975,181 | $1.48B |
| fmr llc | 3,693,610 | $1.10B |
| citadel advisors llc | 1,052,498 | $312.6M |
| hhlr advisors, ltd. | 1,034,306 | $307.2M |
| blackrock, inc. | 657,501 | $195.3M |
| siren, l.l.c. | 465,000 | $138.1M |
| morgan stanley | 464,472 | $137.9M |
| ubs group ag | 415,330 | $123.3M |
| bank of america corp /de/ | 405,273 | $120.4M |
Showing top 10 of 277 institutional holders of BeOne Medicines Ltd.. Open the full 13F history after sign-in.
Short Interest
as of May 1, 2026- % of float
- 1.5%
- Days to cover
- 5.4
- Shares short
- 1,154,033
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ONC short interestGovernance
Frequently asked questions
What is the AI investment thesis for BeOne Medicines Ltd.?
BeOne Medicines Ltd. is a global biotech company focused on developing and commercializing innovative oncology medicines, with a strong commercial portfolio led by BRUKINSA and a deep pipeline of early- and late-stage candidates.
What is BeOne Medicines Ltd.'s lead drug candidate?
BeOne Medicines Ltd.'s most advanced tracked candidate is brukinsa (Approved).
What is BeOne Medicines Ltd.'s next catalyst?
BeOne Medicines Ltd.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Phase 2 Study of Tislelizumab Administered With Alternative Dosing Schedules Plus Chemotherapy as " — expected August 31, 2026.
Who is the CEO of BeOne Medicines Ltd.?
Mr. John V. Oyler is the chief executive officer of BeOne Medicines Ltd. (ONC).
Where is BeOne Medicines Ltd. headquartered?
BeOne Medicines Ltd. (ONC) is headquartered in Basel, Switzerland.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.